子類別 期刊論文 [327/330] 圖書 [1/1] 會議論文/會議摘要 [115/179] 鄰近社群 于重元 [19/19] 劉柯俊 [85/98] 劉滄梧 [119/125] 劉界元(2003-2010) [3/3] 夏和雄(1996-2012) [26/31] 夏興國 [51/54] 姜乃榕 [82/94] 常慧如 [39/44] 張俊彥 [234/254] 張光裕 [69/79] 張憶壽 [103/106] 張文祥 [52/53] 張書銘 [89/91] 彭汪嘉康(1996-2007) [120/126] 施能耀 [37/43] 李家惠 [29/29] 李岳倫 [48/49] 林素芳 [32/32] 楊奕馨 [41/42] 江士昇 [88/90] 沈哲宏 [14/16] 洪文俊 [88/88] 莊雙恩 [82/91] 蔡坤志 [32/34] 蔡慧珍 [66/71] 蘇勇曄 [40/40] 蘇振良 [24/25] 郭靜娟 [71/76] 陳尚鴻 [45/48] 陳振陽 [72/72] 陳美霞(2002-2009) [1/1] 陳詩政 [2/2] 陳雅雯 [38/39] 黃智興 [55/55] 黃道揚 [26/26] 丁兆治(2000-2004) [5/5] 其他 [464/471] 劉敏(1996-2007) [60/62] 劉玫英(2004-2006) [2/2] 吳成文(1996-2008) [53/55] 曾思文(1997-2007) [4/4] 李冠德(1997-2004) [4/6] 林景太(1999-2007) [5/5] 楊文光(1996-1999) [21/21] 王全正(1996-2003) [4/4] 莊聲宏(1997-2004) [11/11] 詹宗晃(2000-2008) [2/2] 賴基銘(2004-2008) [41/47] 阮麗蓉(2000-2006) [6/7] 陳俊叡(2003-2007) [6/6] 馬彥英(1997-1999) [1/1] 黃奇英(2005-2007) [9/10] 社群統計 近3年內發表的文件:74(14.51%) 含全文筆數:443(86.86%) 文件下載次數統計 下載大於0次:443(100.00%) 下載大於100次:426(96.16%) 檔案下載總次數:178043(3.32%) 最後更新時間: 2024-12-01 03:12 上傳排行 資料載入中..... 下載排行 資料載入中..... 最近上傳 Pan-Asian adapted ESMO clinical pra... Nivolumab plus chemotherapy in pati... Survival of advanced/recurrent gast... Topiramate suppresses peri-infarct ... A phase 1 study of biweekly nab-pac... Plain language summary of the FOENI... Outcomes of post-immunotherapy dura... Durvalumab or placebo plus gemcitab... Impact of previous S-1 treatment on... Chromatin remodeling-related PRDM1 ...

跳至: (選擇年份) 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 1995 1994 1993 1992 1991 1990 1985 1980 1975 1970 1960 1950 (選擇月份) January February March April May June July August September October November December 或輸入年份:

由新到舊排序 由最舊的開始

顯示項目201-225 / 510. (共21頁) << < 4 5 6 7 8 9 10 11 12 13 > >> 每頁顯示[10|25|50]項目

日期	題名	關聯
2018-02	Nivolumab safety profile in Asian and Western patients with chemotherapy-refractory (CTx-R) advanced gastric/gastroesophageal junction (adv G/GEJ) cancer from the ATTRACTION-2 and CheckMate-032 trials	Journal of Clinical Oncology. 2018 Feb;36(4, Suppl.):Abstract number 90.
2018-02	Dose modifications of liposomal irinotecan (nal-IRI)+5-fluorouracil/leucovorin (5-FU/LV) in NAPOLI-1: Impact on efficacy	Journal of Clinical Oncology. 2018 Feb;36(4, Suppl.):388.
2018-02	Subgroup analysis by baseline pain intensity (BPI) and analgesic use (BAU) in NAPOLI-1: A phase III study of liposomal irinotecan (nal IRI)+/- 5-fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) p	Journal of Clinical Oncology. 2018 Feb;36(4, Suppl.):379.
2018-02	Subgroup analysis by baseline (BL) weight-associated parameters: A phase III study of liposomal irinotecan (nal-IRI)+/--5fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with g	Journal of Clinical Oncology. 2018 Feb;36(4, Suppl.):410.
2018-01	Orchestration of H3K27 methylation: Mechanisms and therapeutic implication	Cellular and Molecular Life Sciences. 2018 Jan;75(2):209-223.
2018-01	Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer; A JSMO - ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS	Annals of Oncology. 2018 Jan;29(1):44-70.
2018-01	Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma	Journal of Clinical Oncology. 2018 Jan;36(3):276-282.
2018-01	Environmental tobacco smoke and risk of pancreatic cancer among never smokers	Cancer Science. 2018 Jan;109(Suppl. 1):769.
2018-01	Role of academic institute in cancer therapy development in National Institute of Cancer Research, NHRI in Taiwan	Cancer Science. 2018 Jan;109(Suppl. 1):43.
2018-01	The role of aberrant mitochondrial phosphoenolpyruvate carboxykinase expression in pancreatic neuroendocrine tumors	Cancer Science. 2018 Jan;109(Suppl. 1):466.
2017-12	Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): A randomised, double-blind, placebo-controlled, phase 3 trial	Lancet. 2017 Dec;390(10111):2461-2471.
2017-11	Subgroup analysis by prior non-liposomal irinotecan therapy in NAPOLI-1: A phase 3 study of nal-IRI65-fluorouracil/leucovorin in patients with metastatic pancreatic ductal adenocarcinoma previously treated with gemcitabine-based therapy	Annals of Oncology. 2017 Nov;28(Suppl. 10):67-U261.
2017-11	CA19-9 decrease and overall survival (OS) in the NAPOLI-1 trial of liposomal irinotecan (nal-IRI) � 5-fluorouracil and leucovorin (5-FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy	Annals of Oncology. 2017 Nov;28(Suppl. 10):Meeting Abstract 227P.
2017-10-24	Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan	Journal of the Formosan Medical Association. 2018 May;117(5):381-403.
2017-10-09	Mitochondrial phosphoenolpyruvate carboxykinase (PEPCK-M) regulates the cell metabolism of pancreatic neuroendocrine tumors (pNET) and de-sensitizes pNET to mTOR inhibitors	Oncotarget. 2017 Oct 09;8(61):103613-103625.
2017-10	Anti-angiogenic therapy in patients with advanced gastric and gastroesophageal junction cancer: A systematic review	Cancer Research and Treatment. 2017 Oct;49(4):851-868.
2017-10	First-line antibiotic therapy in Helicobacter pylori-negative low-grade gastric mucosa-associated lymphoid tissue lymphoma	Scientific Reports. 2017 Oct;7:Article number 14333.
2017-09-16	The regulatory role of aberrant Phosphatase and Tensin Homologue and Liver Kinase B1 on AKT/mTOR/c-Myc axis in pancreatic neuroendocrine tumors	Oncotarget. 2017 Sep 16;8(58):98068-98083.
2017-09	KLF10 loss in the pancreas provokes activation of SDF-1 and induces distant metastases of pancreatic ductal adenocarcinoma in the KrasG12D p53flox/flox model	Oncogene. 2017 Sep;36(39):5532-5543.
2017-09	A phase II study of Arginine Deiminase (ADI-PEG20) in relapsed/refractory or poor-risk acute myeloid leukemia patients	Scientific Reports. 2017 Sep;7:Article number 11253.
2017-09	ATTRACTION-04 (ONO-4538-37): A randomized, multicenter, phase 2/3 study of nivolumab (Nivo) plus chemotherapy in patients (Pts) with previously untreated advanced or recurrent gastric (G) or gastroesophageal junction (GEJ) cancer	Annals of Oncology. 2017 Sep;28(Suppl. 5):Meeting Abstract 777TiP.
2017-09	ATTRACTION-05 (ONO-4538-38/BMS CA209844): A randomized, multicenter, double-blind, placebo-controlled Phase 3 study of Nivolumab (Nivo) in combination with adjuvant chemotherapy in pStage III gastric and esophagogastric junction (G/EGJ) cancer	Annals of Oncology. 2017 Sep;28(Suppl. 5):Meeting Abstract 778TiP.
2017-09	Inhibition of the ubiquitin-conjugating enzyme E2B restores the BCNU sensitivity of cancer cells by regulating MGMT ubiquitination	Annals of Oncology. 2017 Sep;28(Suppl. 5):Meeting Abstract 55P.
2017-09	Prognostic value of baseline neutrophil-to-lymphocyte ratio for predicting clinical outcome in metastatic pancreatic ductal adenocarcinoma (mPDAC) patients treated with liposomal irinotecan (nal-IRI)+5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV alon	Annals of Oncology. 2017 Sep;28(Suppl. 5):Meeting Abstract 741P.
2017-09	Mutant KIT translocates into the nucleus and induces NFKBIB expression that leads to KIT expression in imatinib-resistant gastrointestinal stromal tumors	Annals of Oncology. 2017 Sep;28(Suppl. 5):Meeting Abstract 1679P.

顯示項目201-225 / 510. (共21頁) << < 4 5 6 7 8 9 10 11 12 13 > >> 每頁顯示[10|25|50]項目